News | October 09, 2009

CardioPharma Prepares for FDA Submission of Triple-Combination CardiaPill

October 9, 2009 – CardioPharma is beginning the final funding phase before submitting an FDA new drug application (NDA) for CardiaPill, the world's first patented triple-combination cardiovascular polypill.

"The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," said Don Sellers, CardioPharma's chairman and CEO. "After our recent meeting with the FDA we believe the CardiaPill NDA can be submitted within 12 months following our final round of funding."

"The recently released results of the Kaiser Permanente ALL (aspirin, lisinopril, lovastatin) initiative provide clinical and economic insight into the significant need for effective, low-cost combination cardiovascular products," said Carlos Ferrario, M.D., professor of hypertension and vascular diseases at Wake Forest University, an adviser to CardioPharma and other cardiovascular interest groups. "What was even more remarkable," Dr. Ferrario added," is that this study showed positive results in two years, where prior studies viewing agents separately took five years to reach consistently positive results. This data shows that placing this combination of aspirin, ACE-I or ARB, and statin in one pill is an idea whose time has arrived, especially given these outcomes."

The company said there is a recognized unmet need for a cardiovascular product that both simplifies and enhances compliance, and CardiaPill is a product that is less expensive with fewer copays, one dispensing fee, less paperwork and ultimately reduced hospitalization.

CardioPharma is not alone in the competition to put a cardiovascular polypill into the marketplace. In Asia, Cipla and Dr. Reddy's have been trying for years and in Spain a group working with Ferrer Laboratories discussed clinical trials in Latin America in 2008. Since Wald and Law in the U.K. first noted the need for such products, researchers around the world have sought without success to develop a practical polypill.

For more information: www.cardio-pharma.com

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init